IL17A and diabetes mellitus: Consequently, a refined selection comprising seven genes (MMP2, MMP9, IL17A, IL10, FGF2, IL6 and VEGFA) and eleven pharmacological agents has emerged, exhibiting promise in delivering therapeutic effects aimed at mitigating the occurrence of OP in individuals afflicted with diabetes.